These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 19183194

  • 1. Rediscovering alemtuzumab: current and emerging therapeutic roles.
    Gribben JG, Hallek M.
    Br J Haematol; 2009 Mar; 144(6):818-31. PubMed ID: 19183194
    [Abstract] [Full Text] [Related]

  • 2. Alemtuzumab in the treatment of chronic lymphocytic leukemia.
    Robak T.
    BioDrugs; 2005 Mar; 19(1):9-22. PubMed ID: 15691213
    [Abstract] [Full Text] [Related]

  • 3. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.
    Chakraverty R, Orti G, Roughton M, Shen J, Fielding A, Kottaridis P, Milligan D, Collin M, Crawley C, Johnson P, Clark A, Parker A, Bloor A, Pettengell R, Snowden J, Pettitt A, Clark R, Hale G, Peggs K, Thomson K, Morris E, Mackinnon S.
    Blood; 2010 Oct 21; 116(16):3080-8. PubMed ID: 20587785
    [Abstract] [Full Text] [Related]

  • 4. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
    Alinari L, Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC.
    Oncogene; 2007 May 28; 26(25):3644-53. PubMed ID: 17530018
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Alemtuzumab in stem cell transplantation.
    Hale G.
    Med Oncol; 2002 May 28; 19 Suppl():S33-47. PubMed ID: 12180491
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
    Hale G, Slavin S, Goldman JM, Mackinnon S, Giralt S, Waldmann H.
    Bone Marrow Transplant; 2002 Dec 28; 30(12):797-804. PubMed ID: 12476271
    [Abstract] [Full Text] [Related]

  • 9. Alemtuzumab in B-cell chronic lymphocytic leukemia.
    Shapira I, Grossbard ML.
    Clin Lymphoma; 2004 Mar 28; 4(4):228-9. PubMed ID: 15072614
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of alemtuzumab and the relevance in clinical practice.
    Elter T, Molnar I, Kuhlmann J, Hallek M, Wendtner C.
    Leuk Lymphoma; 2008 Dec 28; 49(12):2256-62. PubMed ID: 19052972
    [Abstract] [Full Text] [Related]

  • 11. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia.
    De Decker M, Bacher K, Thierens H, Slegers G, Dierckx RA, De Vos F.
    Nucl Med Biol; 2008 Jul 28; 35(5):599-604. PubMed ID: 18589304
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis.
    Jordan MB, McClain KL, Yan X, Hicks J, Jaffe R.
    Pediatr Blood Cancer; 2005 Mar 28; 44(3):251-4. PubMed ID: 15390358
    [Abstract] [Full Text] [Related]

  • 14. The role of alemtuzumab in nonmyeloablative hematopoietic transplantation.
    Giralt S.
    Semin Oncol; 2006 Apr 28; 33(2 Suppl 5):S36-43. PubMed ID: 16720202
    [Abstract] [Full Text] [Related]

  • 15. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
    Nabhan C, Patton D, Gordon LI, Riley MB, Kuzel T, Tallman MS, Rosen ST.
    Leuk Lymphoma; 2004 Nov 28; 45(11):2269-73. PubMed ID: 15512816
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.
    Osuji N, Del Giudice I, Matutes E, Morilla A, Owusu-Ankomah K, Morilla R, Dunlop A, Catovksy D.
    Leuk Lymphoma; 2005 May 28; 46(5):723-7. PubMed ID: 16019510
    [Abstract] [Full Text] [Related]

  • 19. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond.
    Dumont FJ.
    Expert Rev Anticancer Ther; 2002 Feb 28; 2(1):23-35. PubMed ID: 12113063
    [Abstract] [Full Text] [Related]

  • 20. Current and emerging treatments for chronic lymphocytic leukaemia.
    Robak T, Jamroziak K, Robak P.
    Drugs; 2009 Feb 28; 69(17):2415-49. PubMed ID: 19911856
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.